Watch CNTB. Know when insiders buy.
One email the day a filing lands. Free.
CNTB
Connect Biopharma Holdings Ltd
2.06
+0.05 +2.49%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
83
PASS · shorts 83
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $129.7MP/E —DIV YIELD —FCF YIELD -46.74%REV TTM $3M +50.3%NET INCOME −$69MNET CASH —52W 1.32 – 3.69SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.8M | +5666.7% | — | −$17.6M | −$17.3M | — | -0.27 | −$15.9M | $0 | −$15.9M | Aug 12 |
| Q1 2026 · Mar 31 | $169K | — | — | −$19.6M | −$19.4M | — | -0.34 | −$16M | $0 | −$16M | Aug 12 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$15.5M | −$15.1M | — | -0.27 | −$11.3M | $16K | −$11.3M | Mar 31 |
| Q3 2025 · Sep 30 | $16K | −98.7% | — | −$17.7M | −$17.2M | — | -0.31 | −$17.4M | $34K | −$17.4M | Nov 12 |
| Q2 2025 · Jun 30 | $48K | −99.8% | — | −$13.4M | −$12.9M | −186.9% | -0.23 | −$12.6M | $303K | −$12.9M | Aug 12 |
| Q1 2025 · Mar 31 | $0 | — | — | −$11.4M | −$10.3M | — | -0.19 | −$10M | $81K | −$10M | Aug 12 |
| Q4 2024 · Dec 31derived | $698K | — | — | −$9.6M | −$8.9M | — | -0.16 | −$2.3M | $313K | −$2.6M | Mar 31 |
| Q3 2024 · Sep 30 | $1.2M | — | — | −$13.8M | −$12.9M | — | -0.23 | −$13M | $147K | −$13.2M | Nov 12 |
| Q2 2024 · Jun 30 | $24.1M | — | — | $13.6M | $14.8M | — | 0.27 | −$7.7M | $290K | −$8M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$12.6M | −$8.7M | — | -0.16 | −$591K | $0 | −$591K | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $64K | — | −$58.1M | −$55.5M | -86687.5% | -1.00 | −$51.2M | $434K | −$51.6M | — | — |
| FY2024 · to Dec 31 | $26M | — | −$22.5M | −$15.6M | -60.0% | -0.28 | −$23.6M | $750K | −$24.4M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$69.1M | −$62.1M | — | -1.13 | −$47.7M | $81K | −$47.8M | — | — |
Every number comes from Connect Biopharma Holdings Ltd's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.